Last $0.19 USD
Change Today 0.00 / 0.00%
Volume 184.5K
AVXL On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

anavex life sciences corp (AVXL) Snapshot

Open
$0.19
Previous Close
$0.19
Day High
$0.19
Day Low
$0.19
52 Week High
03/10/14 - $0.60
52 Week Low
12/1/14 - $0.15
Market Cap
10.7M
Average Volume 10 Days
330.1K
EPS TTM
$-0.29
Shares Outstanding
56.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ANAVEX LIFE SCIENCES CORP (AVXL)

Related News

No related news articles were found.

anavex life sciences corp (AVXL) Related Businessweek News

No Related Businessweek News Found

anavex life sciences corp (AVXL) Details

Anavex Life Sciences Corp., a biopharmaceutical company, is engaged in the discovery and development of drugs for the treatment of Alzheimer’s disease, central nervous system diseases, and pain and various cancers. Its lead drug candidates include ANAVEX 2-73 and ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), which is in a Phase IIa clinical trial for the treatment of Alzheimer’s disease. The company’s product candidates also include ANAVEX 3-71, a drug candidate that is effective in very small doses against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice via sigma-1 receptor activation and M1 muscarinic allosteric modulation; ANAVEX 1-41, a sigma-1 agonist for neuroprotective application; and ANAVEX 1037, ANAVEX 1079, and ANAVEX 1519 for the treatment of pain and various cancers. Anavex Life Sciences Corp. was founded in 2006 and is headquartered in New York, New York.

4 Employees
Last Reported Date: 12/29/14
Founded in 2006

anavex life sciences corp (AVXL) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $640.0K
Compensation as of Fiscal Year 2014.

anavex life sciences corp (AVXL) Key Developments

Amarantus Announces First Alzheimer's Biomarker Services Collaboration for LymPro Test(R) with Anavex Life Sciences Corp

Amarantus BioScience Holdings Inc. and Anavex Life Sciences Corp. announced the execution of a biomarker services agreement in which Amarantus will evaluate the pharmacodynamic effect of ANAVEX 2-73 and ANAVEX PLUS on the expression of the biomarker CD69 in specific sub-populations of peripheral blood lymphocytes using Amarantus' proprietary Alzheimer's blood diagnostic LymPro Test®. In parallel, the companies have entered into a Letter of Intent ("LOI") for Amarantus to assist Anavex in planning the scope of the blood-based biomarker components of Anavex' next larger, potentially Phase 3, Alzheimer's disease clinical trial that is expected to follow the ongoing Phase 2a study currently enrolling subjects to collect additional safety and exploratory efficacy data in mild to moderate AD patients. Initial data from Anavex' Phase 2a AD trial is expected in the third quarter of 2015. ANAVEX 2-73 and ANAVEX PLUS, which combines ANAVEX 2-73 with donepezil (Aricept®), are Anavex' lead drug candidate and drug candidate combination, respectively, for Alzheimer's disease.

Anavex Life Sciences Corp. Announces Earnings Results for the Three Months Ended December 31, 2014

Anavex Life Sciences Corp. announced earnings results for the three months ended December 31, 2014. For the period, the company reported operating loss of $770,678 against $309,608 a year ago. Net loss was $786,718 or $0.02 per basic and diluted share against net profit of $358,637 or $0.01 per basic and diluted share a year ago.

Anavex Life Sciences Corp. Proposes Amendments to the Articles of Incorporation

Anavex Life Sciences Corp. announced that the company will approve amendment of the company's articles of incorporation to increase the amount of authorized shares of common stock from 150,000,000 to 400,000,000 shares and approve the amendment of the company's articles of incorporation to authorize up to 10,000,000 shares of blank-check preferred stock.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AVXL:US $0.19 USD 0.00

AVXL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AVXL.
View Industry Companies
 

Industry Analysis

AVXL

Industry Average

Valuation AVXL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 22.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANAVEX LIFE SCIENCES CORP, please visit www.anavex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.